Levels of Metalloproteinase (MMP-3, MMP-9), NF-kB Ligand (RANKL), and Nitric Oxide (NO) in Peripheral Blood of Osteoarthritis (OA) Patients
Levels of Metalloproteinase (MMP-3, MMP-9), NF-kB Ligand (RANKL), and Nitric Oxide (NO) in Peripheral Blood of Osteoarthritis (OA) Patients
复制标题
DOI：
10.7754/clin.lab.2011.110823
复制
发表时间：
2012-01-01
影响因子：
0.7
通讯作者：
Wang, Dan
中科院分区：
文献类型：
--
作者：
Li, Heng;Li, Liqin;Wang, Dan
背景资料：本研究的目的是判断是否有一些生化特征的膝关节骨关节炎的血液和临床特征之间的相关性，并评估骨关节炎（OA）的严重程度和推定的生物标志物之间的潜在关系为diseases.Methods：105例膝关节OA患者进行了临床分析（Lequesne的指数）和放射学（Kellgren和劳伦斯，K&L）。分别收获血浆和外周血单核细胞（PBMC）。分析标本中一氧化氮（NO）、基质金属蛋白酶-3（MMP-3）和基质金属蛋白酶-9（MMP-9）的浓度。结果：OA早期（I级）血浆MMP-3、MMP-9、NO浓度及RANKL mRNA、MMP-9 mRNA转录水平均显著升高，与正常对照组比较差异有统计学意义（P < 0. 05）。血浆MMP-3、MMP-9含量及PBMC中MMP-9 mRNA表达水平与早期OA临床症状严重程度（Lequesne's总分）呈正相关。血浆中NO含量与早期OA患者（I级）的Lequesne总评分、压力反应性疼痛评分和肿胀评分相关。类似地，在I级OA患者中，RANKL mRNA表达与总Lequesne评分、压力反应疼痛评分和肿胀评分呈正相关。一些生化指标，包括NO、MMP-3、MMP-9的含量，以及MMP-9 mRNA和RANKL mRNA的转录水平，当放射学特征不能反映关节软骨退化时，在OA病理过程的早期诊断OA疾病可能具有足够的特异性和敏感性。因此，适当调节这些因子可能是治疗退行性骨关节疾病的一个有前途和现实的新靶点。（临床实验室2012;58：755-762. DOI：10.7754/Clin.Lab.2011.110823）
Background: The aim of this study was to judge whether there is a correlation between some biochemical features of knee osteoarthritic blood and clinical characteristics and to evaluate the potential relationship between osteoarthitis (OA) severity and putative biomarkers for the disease.Methods: 105 patients suffering from knee OA were analyzed clinically (Lequesne's index) and radiographically (Kellgren and Lawrence, K&L). Plasma and peripheral blood mononuclear cells (PBMC) were harvested separately. Specimens were analyzed for concentrations of nitric oxide (NO), matrix metalloproteinase-3 (MMP-3), and matrix metalloproteinase-9 (MMP-9). Transcript levels of the receptor activator of NF-kB ligand (RANKL) mRNA, MMP-3mRNA, and MMP-9mRNA were measured using real-time quantitative RT-PCR.Results: Data certified significantly increasing concentrations of plasma MMP-3, MMP-9, and NO as well as transcript levels of RANKL mRNA and MMP-9 mRNA in early OA (at grade I). There was a positive correlation of MMP-3 and MMP-9 content in plasma and MMP-9 mRNA expression levels in PBMC with the severity of clinical symptoms (total Lequesne's scores) in early OA. NO content in plasma correlated with total Lequesne's scores, pain scores in response to pressure, and swelling scores of early OA patients (atgGrade I). Analogously, there were positive correlations of RANKL mRNA expression with total Lequesne's scores, pain scores in response to pressure, and swelling scores in OA patients at Grade I.Conclussions: Some biochemical factors, including content of NO, MMP-3, MMP-9, and transcript levels of some genes, including MMP-9 mRNA and RANKL mRNA, may be specific and sensitive enough to diagnose OA diseases at an early stage in the pathological process of OA when radiological features do not reflect degradation of articular cartilage. Therefore, proper regulation of these factors may be a promising and realistic new target for the treatment of degenerative osteoarticular diseases. (Clin. Lab. 2012;58:755-762. DOI: 10.7754/Clin.Lab.2011.110823)